<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00883259</url>
  </required_header>
  <id_info>
    <org_study_id>12/2008</org_study_id>
    <nct_id>NCT00883259</nct_id>
  </id_info>
  <brief_title>Metformin and Gestational Diabetes in High-risk Patients: a RCTs</brief_title>
  <official_title>Metformin Treatment for Preventing Gestational Diabetes in High-risk Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Magna Graecia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Magna Graecia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gestational diabetes mellitus (DM) is one of the most frequent complications in pregnant
      patients with polycystic ovary syndrome (PCOS) in 20-40% of cases and ~40% of patients with
      gestational DM are likely to have underlying polycystic ovarian morphology. A recent
      meta-analysis demonstrated a significantly higher risk of developing gestational DM [odds
      ratio (OR) 2.94; 95% confidence interval (CI): 1.70-5.08] in the PCOS population.

      Metformin is an oral biguanide insulin sensitizer used for treating type-2 DM and recently
      introduced to treat PCOS.

      At the moment, preliminary data seem to reassure regarding the use of metformin in PCOS
      patients showing benefits for maternal and fetal outcomes, without serious adverse events.
      Furthermore, well-designed randomized, controlled trials (RCTs) on this issue are lacking,
      thus it is not possible to either suggest or advice against the use of metformin during
      pregnancy for reducing gestational DM risk. To this regard, PCOS represents an intriguing
      model of &quot;high-risk patients&quot; to evaluate the efficacy of metformin for preventing DM
      development.

      The present protocol firstly will evaluate the effects of metformin administration in
      reducing incidence of gestational DM in high-risk patients, such as pregnant PCOS patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obese pregnant PCOS patients with previous diagnosis of gestational DM will be enrolled and
      allocated into two treatment arms (experimental and placebo groups). Subjects in the
      experimental group will receive metformin at dosage of 850 mg twice daily, whereas subjects
      in the control group will receive placebo tablets (microcristallyne cellulose) twice daily.

      At baseline, all subjects will undergo clinical evaluation, serial ultrasound examinations,
      and venous blood drawing to evaluate complete hormonal assays and serum fasting glucose and
      insulin levels. The homeostasis model of assessment-insulin resistance, the fasting
      glucose-to-insulin ratio, and the free androgen index will be also calculated. Monthly
      follow-up visits will be performed for assessing maternal and fetal wellbeing.

      The primary endpoint of the study will be the incidence of gestational DM. The power analysis
      and the sample size calculation, performed using SamplePower release 2.0, showed that we will
      need to enroll at least 40 patients for each group to yield a statistically significant
      result with a power study of 90%. For categorical variables, the Pearson chi-square test will
      be performed. Continuous data will be expressed either as mean and standard deviation or
      median and inter-quartile range with min-max values, according to their normal distribution,
      and analysed using the Student t test or Mann-Whitney U test, respectively. Statistical
      significance will be set at P&lt;0.05. The Statistics Package for Social Science (SPSS 14.0.1;
      Chicago, IL, USA) will be used for statistical analysis.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2013</start_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of gestational DM in high-risk patients</measure>
    <time_frame>36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Abortion</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy-induced hypertension</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-eclampsia</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Macrosomia</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fetal malformations</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Premature deliveries</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intrauterine deaths</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Obesity</condition>
  <condition>Polycystic Ovary Syndrome</condition>
  <condition>Gestational Diabetes</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>850 mg twice daily</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Microcristallyne cellulose 1 table twice daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant women with Polycystic Ovary Syndrome (using ASRM/ESHRE criteria)

          -  BMI &gt; 30

          -  Previous diagnosis of gestational DM

        Exclusion Criteria:

          -  Major medical conditions

          -  Organic pelvic diseases

          -  Previous pelvic surgery
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefano Palomba, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Obstetrics &amp; Gynecology - University Magna Graecia of Catanzaro</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesco Orio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Endocrinology - University &quot; Parthenope&quot; of Naples</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Achille Tolino, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Obstetrics &amp; Gynecology, University of Naples</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tommaso Simoncini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Obstetrics &amp; Gynecology - University of Pisa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fulvio Zullo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynecologic Unit, Cancer Center of Excellence &quot;Tommaso Campanella&quot; of Catanzaro</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefano Palomba, MD</last_name>
    <phone>+39-0961-883234</phone>
    <email>stefanopalomba@tin.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pugliese Hospital</name>
      <address>
        <city>Catanzaro</city>
        <state>Catanzaro, CZ</state>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Pugliese&quot; Hospital</name>
      <address>
        <city>Catanzaro</city>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ingrid Tomaino, MD</last_name>
      <phone>+39-0961-883234</phone>
      <email>angela.falbo@libero.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Catanzaro, Italy</name>
      <address>
        <city>Catanzaro</city>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 16, 2009</study_first_submitted>
  <study_first_submitted_qc>April 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2009</study_first_posted>
  <last_update_submitted>April 5, 2013</last_update_submitted>
  <last_update_submitted_qc>April 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Magna Graecia</investigator_affiliation>
    <investigator_full_name>Stefano Palomba</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>High-risk patients</keyword>
  <keyword>Metformin</keyword>
  <keyword>PCOS</keyword>
  <keyword>Pregnancy complications</keyword>
  <keyword>Previous gestational DM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Diabetes, Gestational</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

